APLM
Companies
NASDAQ
Apolomics Inc.
Health Care
$5.20
-$4.55 (-46.67%)
Price Chart
Overview
About APLM
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Market Cap
$23.6M
Volume
396.9K
Avg. Volume
160.8K
P/E Ratio
-7.8307695
Dividend Yield
0.00%
Employees
39.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.04
Low Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, APLM shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025